; or (C) denying the request is necessary to protect the public health. (3) Effect of certification (A) In general (i) Approved uses A designated State medical cannabis product for which a certification is granted under paragraph (2) is deemed, alone or in combination, as medically appropriate, with another designated State medical cannabis product or products for which a certification or certifications have been granted, to be sold in interstate commerce as a non-drug designated State medical cannabis product, for the following indications for use: (I) The treatment of arthritis. (II) The treatment of chemotherapy-induced and non-chemotherapy-induced nausea and vomiting. (III) The stimulation of appetite. (IV) The treatment of the symptoms of patients with HIV/AIDS or for anorexia associated with AIDS. (V) The treatment of temporary or chronic pain and analgesia. (VI) The treatment of muscle spasms. (VII) The treatment of insomnia and restlessness. (VIII) The treatment of post-traumatic stress disorder. (IX) The treatment of chronic pain due to sickle cell disease. (X) Any other indication for use consistent with State medical cannabis law and medical cannabis labeling practice in the State in which the product is to be sold to the end consumer. (XI) Any other indication for use for a designated State medical cannabis product or combination of designated State medical cannabis products deemed appropriate by the Secretary, unless any period of exclusivity for a new drug under clause (iii) or (iv) of section 355(c)(3)(E) of this title, clause (iii) or (iv) of section 355(j)(5)(F) of this title, or section 360cc of this title, or the extension of any such period under section 355a of this title, applicable to such indication for use for such medical cannabis product or combination of products has not expired. (ii) Labeling The requirements of sections 353(b)(4) and 352(f) of this title are deemed to have been met for a designated State medical cannabis product if the labeling on the final use container for such